Dexcom's first G-series CGM, the G4 Platinum, received a CE mark[8] and FDA approval in 2012[9] for adults ages 18 and over. This new device improved hypoglycemic accuracy by 30%.[10] It also offered a longer range of transmission between the sensor and receiver as well as a color LCD display.[11] The G4 Platinum was later approved by the FDA for use in patients ages 2–17 in February 2014.[12] Dexcom then received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps.[13] The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device,[14] the G5 has Bluetooth built into the transmitter, enabling it to send data to the a mobile device.[15] This allows for use of the device without the standalone receiver. The Dexcom G5 then received a CE Mark in September 2015.[16]